Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

435801 Licofelone, Potassium Salt, Monohydrate - CAS 156897-06-2 - Calbiochem

435801
Purchase on Sigma-Aldrich

Overview

Replacement Information

Products

Catalogue NumberPackaging Qty/Pack
435801-25MG Glass bottle 25 mg
Description
OverviewA cell-permeable, orally active arylpyrrolizine carboxylate that is structurally and pharmacologically similar to, but less potent than, MK-886 (Cat. No. 475889). Effectively suppresses cellular Cox pathway PGE2 production by inhibiting COX-1 and mPGES-1, but not COX-2 (IC50 = 0.8, 6, and >30 µM, respectively), and inhibits cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation (IC50 = 0.18 to 3.6 µM against ionophore-stimulated LB4 production from bovine and human PMNL, respectively) by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity. Unlike NSAIDs that target only COX pathway, Licofelone does not cause gastrointestinal damages when applied in vivo.
Catalogue Number435801
Brand Family Calbiochem®
Synonyms2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl, 2,3-dihydro-1H-pyrrolizine-5-yl)-acetic acid, ML3000, ML-3000, COX-1 Inhibitor V, FLAP Inhibitor II, mPGES-1 Inhibitor II
References
ReferencesLaufer, S. A., et al. 1994. Arzneimittelforschung. 44, 629.
Laufer, S., et al. 1994. Arzneimittelforschung. 45, 27.
Wallace, J. L., et al. 1994. Eur J Pharmacol. 271, 525.
Alvaro-Garcia, J. M., et al. 2004. Rheumatology. 43 Supple1, i21.
Koeberle, A., et al. 2008. J Pharmacol Exp Ther. 326, 975.
Fischer, L., et al. 2007. Br J Pharmacol. 152, 471.
Laufer, S. A., et al. 1994. J Med Chem. 37, 1894.
Vidal, C., et al. 2007. J Pharmacol Exp Ther. 320, 108.
Liedtke, A. J., et al. 2009. J Med Chem. 52, 4968.
Bias, P., et al. 2004. Am J Gastroenterol. 99, 611.
Product Information
CAS number156897-06-2
FormWhite powder
Hill FormulaC₂₃H₂₁ClKNO₂•H₂O
Chemical formulaC₂₃H₂₁ClKNO₂•H₂O
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary Target5-LOX
Primary Target IC<sub>50</sub>0.21 µ
Secondary targetCOX
Purity≥99% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsUnstable in solution. Reconstitute just prior to use.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

References

Reference overview
Laufer, S. A., et al. 1994. Arzneimittelforschung. 44, 629.
Laufer, S., et al. 1994. Arzneimittelforschung. 45, 27.
Wallace, J. L., et al. 1994. Eur J Pharmacol. 271, 525.
Alvaro-Garcia, J. M., et al. 2004. Rheumatology. 43 Supple1, i21.
Koeberle, A., et al. 2008. J Pharmacol Exp Ther. 326, 975.
Fischer, L., et al. 2007. Br J Pharmacol. 152, 471.
Laufer, S. A., et al. 1994. J Med Chem. 37, 1894.
Vidal, C., et al. 2007. J Pharmacol Exp Ther. 320, 108.
Liedtke, A. J., et al. 2009. J Med Chem. 52, 4968.
Bias, P., et al. 2004. Am J Gastroenterol. 99, 611.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision14-June-2013 JSW
Synonyms2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl, 2,3-dihydro-1H-pyrrolizine-5-yl)-acetic acid, ML3000, ML-3000, COX-1 Inhibitor V, FLAP Inhibitor II, mPGES-1 Inhibitor II
DescriptionA cell-permeable, orally active arylpyrrolizine carboxylate that is both structurally and pharmacologically similar to, but less potent than, MK-886 (Cat. No. 475889). Both MK-886 and Licofelone effectively suppress cellular Cox pathway PGE2 (prostaglandin E2) production by inhibiting COX-1 and mPGES-1 (microsomal PGE2 synthase-1), but not COX-2 (IC50 = 0.8, 6, and >30 µM, respectively, by Licofelone), and both compounds suppress cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation (IC50 = 0.18 to 3.6 µM against ionophore-stimulated bovine and human PMNL LB4 production by Licofelone) by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity (No inhibition up to 10 µM Licofelone). Unlike NSAIDs (nonsteroidal antiinflammatory drugs) that target only COX pathway, Licofelone does not cause gastrointestinal damages when applied in vivo.
FormWhite powder
Intert gas (Yes/No) Packaged under inert gas
CAS number156897-06-2
Chemical formulaC₂₃H₂₁ClKNO₂•H₂O
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (100 mg/ml)
Storage -20°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsUnstable in solution. Reconstitute just prior to use.
Toxicity Standard Handling
ReferencesLaufer, S. A., et al. 1994. Arzneimittelforschung. 44, 629.
Laufer, S., et al. 1994. Arzneimittelforschung. 45, 27.
Wallace, J. L., et al. 1994. Eur J Pharmacol. 271, 525.
Alvaro-Garcia, J. M., et al. 2004. Rheumatology. 43 Supple1, i21.
Koeberle, A., et al. 2008. J Pharmacol Exp Ther. 326, 975.
Fischer, L., et al. 2007. Br J Pharmacol. 152, 471.
Laufer, S. A., et al. 1994. J Med Chem. 37, 1894.
Vidal, C., et al. 2007. J Pharmacol Exp Ther. 320, 108.
Liedtke, A. J., et al. 2009. J Med Chem. 52, 4968.
Bias, P., et al. 2004. Am J Gastroenterol. 99, 611.